Circassia Pharmaceuticals Plc (CIR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Circassia Pharmaceuticals Plc (CIR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9783
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Circassia Pharmaceuticals plc (Circassia) develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company’s marketed products include Niox used to assist asthma management and Tudorza for the treatment of chronic obstructive pulmonary disease. The company had several inhaled medicines in pipeline intended for the treatment chronic obstructive pulmonary disease (COPD), which include single and combination dose products. The company offers its products to COPD and asthma specialists in the US, the UK, Germany and other countries through its network of partners. Circassia is headquartered in Oxford, England, the UK.

Circassia Pharmaceuticals Plc (CIR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Circassia Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 9
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Circassia Pharma Acquires US Rights to Two COPD Products from AstraZeneca 11
Partnerships 13
Prosonix Enters Into Research Agreement With Imperial College London 13
Licensing Agreements 14
Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 14
Equity Offering 15
Circassia Pharma Raises USD433.4 Million in Private Placement of Shares 15
Circassia Pharma Completes IPO For US$335.6 Million 16
Aerocrine Completes Private Placement Of Shares For US$15 Million 17
Acquisition 18
AstraZeneca to Acquire Additional 5.7% Stake in Circassia Pharma 18
Circassia Pharma Acquires Prosonix for USD157.6 Million 19
Circassia Pharmaceuticals Plc – Key Competitors 21
Circassia Pharmaceuticals Plc – Key Employees 22
Circassia Pharmaceuticals Plc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Sep 27, 2018: Circassia – Interim results for the six months ended 30 June 2018 24
Apr 24, 2018: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2017 28
Sep 27, 2017: Circassia Pharmaceuticals: Interim Results for the Six Months Ended 30 June 2017 29
Apr 25, 2017: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2016 30
Corporate Communications 31
Feb 13, 2018: Circassia Announces Changes to its Board of Directors 31
Apr 25, 2017: Circassia Announces Non-Executive Director Retirements 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Circassia Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 9
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Circassia Pharma Acquires US Rights to Two COPD Products from AstraZeneca 11
Prosonix Enters Into Research Agreement With Imperial College London 13
Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 14
Circassia Pharma Raises USD433.4 Million in Private Placement of Shares 15
Circassia Pharma Completes IPO For US$335.6 Million 16
Aerocrine Completes Private Placement Of Shares For US$15 Million 17
AstraZeneca to Acquire Additional 5.7% Stake in Circassia Pharma 18
Circassia Pharma Acquires Prosonix for USD157.6 Million 19
Circassia Pharmaceuticals Plc, Key Competitors 21
Circassia Pharmaceuticals Plc, Key Employees 22
Circassia Pharmaceuticals Plc, Subsidiaries 23

List of Figures
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Circassia Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Circassia Pharmaceuticals Plc (CIR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Spark New Zealand Ltd (SPK):企業の財務・戦略的SWOT分析
    Spark New Zealand Ltd (SPK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Sinohydro Corporation Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Sinohydro Corporation Co., Ltd (Sinohydro), a subsidiary of China Hydropower Construction Group International Engineering Co., Ltd., is an engineering and construction company. Its portfolio of services includes general construction, engineering, procurement and construction (EPC), and inves …
  • Ework Group AB (EWRK):企業の財務・戦略的SWOT分析
    Ework Group AB (EWRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Ngai Hing Hong Co Ltd (1047)
    Ngai Hing Hong Co Ltd (1047) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Hammerson plc:企業のM&A・事業提携・投資動向
    Hammerson plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hammerson plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Berkshire Hathaway Energy Co:企業の戦略的SWOT分析
    Berkshire Hathaway Energy Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • African Development Bank Group:企業の戦略的SWOT分析
    African Development Bank Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • GlySens Inc:医療機器:M&Aディール及び事業提携情報
    Summary GlySens Inc (GlySens) is a medical device company that offers glucose monitoring systems. The company develops GlySens ICGM system, a fully-implanted continuous glucose monitoring system intended to improve the lives of people with diabetes. GlySens offers continuous glucose sensor, which ha …
  • P.T. Telekomunikasi Selular:企業の戦略・SWOT・財務情報
    P.T. Telekomunikasi Selular - Strategy, SWOT and Corporate Finance Report Summary P.T. Telekomunikasi Selular - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • InVitae Corp (NVTA):製薬・医療:M&Aディール及び事業提携情報
    Summary Invitae Corp (Invitae), formerly Locus Development Inc, is a genetic information company which processes DNA-containing samples, analyzes information about patient-specific genetic variation and generates test reports for clinicians and their patients. The company’s portfolio of diagnostic t …
  • Graftys SA:製品パイプライン分析
    Summary Graftys SA (Graftys) is a medical device company that focuses on the development, manufacture and commercialization of synthetic bioactive orthopedic biomaterials. It provides a wide range of synthetic and bioresorbable bone graft substitutes and other cement products. The company’s products …
  • Sanofi (SAN):企業の財務・戦略的SWOT分析
    Sanofi (SAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Indeck Energy Services Inc:企業の戦略的SWOT分析
    Indeck Energy Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Green Cross LabCell Corp (144510):製薬・医療:M&Aディール及び事業提携情報
    Summary Green Cross LabCell Corp (GCLabCell), a subsidiary of GC Pharma, is a biotechnology company that offers biopharmaceuticals. The company’s products include specialty medicines, blood products and vaccines, generic drugs, parenteral products, and genetically-modified hemophilia A drug Greenjun …
  • CDK Global, Inc. (CDK):企業の財務・戦略的SWOT分析
    CDK Global, Inc. (CDK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Gammon India Ltd (GAMMONIND):企業の財務・戦略的SWOT分析
    Gammon India Ltd (GAMMONIND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Charoen Pokphand Foods Public Co Ltd (CPF):企業の戦略的SWOT分析
    Charoen Pokphand Foods Public Co Ltd (CPF) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Kinross Gold Corporation:企業のM&A・事業提携・投資動向
    Kinross Gold Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kinross Gold Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Genmab AS (GEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Genmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company's marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple m …
  • Karambunai Corporation Berhad:企業の戦略・SWOT・財務分析
    Karambunai Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary Karambunai Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆